ClinicalTrials.gg
TerminatedNCT00249002Updated Nov 25, 2019Results posted

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

A Phase 2 interventional study of ABI-007 in Hemodialysis Graft Dysfunction, sponsored by Celgene. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Prevention

Why this study was terminated
Terminated due to pipeline prioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.

Read the detailed description

This is an open-label, pilot, phase II study to assess the feasibility of administering ABI-007 intravenously [IV] over 3-5 minutes to patients with hemodialysis graft dysfunction (i.e., either a thrombosed polytetrafluoroethylene (PTFE) graft, or a patent but dysfunctional PTFE graft). Patients with graft dysfunction who are successfully treated with angioplasty will start treatment after angioplasty or during their first dialysis through the graft following intervention, and will receive 3 subsequent treatments of ABI-007 at 35 mg/m\^2 on weeks 5, 13 and 21.

02

Conditions studied

  • Hemodialysis Graft Dysfunction

Keywords

  • Vascular Access Graft Failure
  • Venous Neointimal Hyperplasia(VNH)
  • Hemodialysis
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Thrombosed graft within the past 7 days or a patent but dysfunctional polytetrafluoroethylene (PTFE) graft (identified by any means) with a stenosis of greater than 50% at the graft-vein anastomosis or within 8 centimeters of the graft-vein anastomosis which will be referred to as the index lesion. Following angioplasty patients must have residual stenosis of less than 20% post angioplasty for the index lesion and for all other stenoses; also index lesion must be located in the arm. PTFE graft requiring angioplasty must be at least 30 days old.
  • Male or non-pregnant and non-lactating female, and ≥ 18 years of age.
  • Patient or guardian has provided a signed written for the administration of ABI-007 (post-angioplasty or at the time of first dialysis through the new graft) using a form that is approved by the local IRB/ethics committee of the investigative site.
  • Patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent form prior to participation in any study-related activities.

Exclusion criteria

Exclusion Criteria:

  • Use of a stent at the time of current angioplasty or at any previous time in the index lesion.
  • No perforation at the time of current angioplasty.
  • Thrombosed graft for more than 7 days.
  • Patient has the following blood counts at baseline:
  • (ANC) \< 2.0*10\^9/L;
  • \< 100*10\^9/L;
  • (Hgb) \< 9 g/dL.
  • Patient has the following blood chemistry levels at baseline:
  • (AST or SGOT), alanine transaminase (ALT or SGPT) > 2.5x (ULN);
  • total ≥ upper limit of normal (ULN);
  • Unable to give , or for whom informed consent cannot be obtained from a legal guardian.
  • Women who are pregnant and women of child bearing potential who do not use adequate .
  • 2 procedures of percutaneous or surgical intervention on the PTFE graft within the previous 90 days.
  • Previous participation in another study with any drug or device within the past 30 days or current enrollment in any other clinical protocol or investigational trial.
  • Patient has a of less than 6 months.
  • Intended kidney transplant within 6 months of enrollment in the study
  • Any significant medical condition which in the investigators opinion may interfere with the patients optimal participation in the study.
  • Patient is, in the investigator's opinion, unlikely to be able to complete the study through the End of Study (EOS) visit.
  • Patient has a history of allergy or to the study drug.
  • Documented hypercoagulable state requiring anti-coagulation (protein S, protein C, antiphospholipid; anticoagulation on an empiric basis for graft thromboses in not a contradiction).
  • Patient is (HIV) positive.
  • Patient is currently receiving other chemotherapy drug(s).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    ABI-007

    ABI-007 35 mg/m\^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21

    Drug: ABI-007

Interventions

  • Also known as: Abraxane®, paclitaxel

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Discontinued, Delayed or Interrupted Therapy

    Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.

    Time frame: up to week 21

  2. Percentage of Participants Without Graft Failure or Need for Intervention

    Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.

    Time frame: 24 weeks

  3. Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12

    Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

    Time frame: 12 weeks

  4. Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24

    Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

    Time frame: 24 weeks

  5. Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9

    Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

    Time frame: 9 months

  6. Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12

    Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

    Time frame: 12 months

  7. Stenosis (%) of a Non-index Lesion Using Angiography at Week 12

    Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

    Time frame: 12 weeks

  8. Stenosis (%) of a Non-index Lesion Using Angiography at Week 24

    Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

    Time frame: 24 weeks

  9. Stenosis (%) of a Non-index Lesion Using Angiography at Month 9

    Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

    Time frame: 9 months

  10. Stenosis (%) of a Non-index Lesion Using Angiography at Month 12

    Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

    Time frame: 12 months

Secondary outcomes

  1. Participants With Arthrosclerotic Cardiovascular Complications

    Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.

    Time frame: up to week 25

  2. Kaplan Meier Estimates for Time to Graft Failure or Intervention

    The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.

    Time frame: up to 12 months

  3. Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks

    The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks.

    Time frame: 24 weeks

07

Results

Posted Mar 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneABI-007
Started9
Completed2
Not completed7
Withdrew: Adverse event2
Withdrew: Study cancellation3
Withdrew: Other2

Outcome measures

PrimaryPercentage of Participants With Discontinued, Delayed or Interrupted Therapy

Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.

Time frame:
up to week 21
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
percentage of participantsABI-007
Delayed dose44
Interrupted0
Discontinued therapy33
PrimaryPercentage of Participants Without Graft Failure or Need for Intervention

Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Without Graft Failure or Need for Intervention
percentage of participantsABI-007
Percentage of Participants Without Graft Failure or Need for Intervention0
PrimaryStenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12

Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

Time frame:
12 weeks
Reported as:
Mean · percentage of stenosis
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12
percentage of stenosisABI-007
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 1261.7 ± 32.51
PrimaryStenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24

Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

Time frame:
24 weeks
Reported as:
Mean · percentage of stenosis
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24
percentage of stenosisABI-007
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 2479.0 ± 11.40
SecondaryParticipants With Arthrosclerotic Cardiovascular Complications

Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.

Time frame:
up to week 25
Reported as:
Number · participants
Participants With Arthrosclerotic Cardiovascular Complications
participantsABI-007
>=1 arthrosclerotic cardiovascular complication4
Bradycardia1
Hypotension1
Hypertrophic obstructive cardiomyopathy1
Carotid artery stenosis1
Cerebrovascular accident1
Cardiovascular disorder1
SecondaryKaplan Meier Estimates for Time to Graft Failure or Intervention

The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.

Time frame:
up to 12 months
Reported as:
Median · weeks
Kaplan Meier Estimates for Time to Graft Failure or Intervention
weeksABI-007
Kaplan Meier Estimates for Time to Graft Failure or Intervention11.4 (11.0 to 12.0)
SecondaryPercentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks

The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks
percentage of participantsABI-007
Index lesion14
Non-Index lesions57
PrimaryStenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9

Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

Time frame:
9 months
Reported as:
Mean · percentage of stenosis
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9
percentage of stenosisABI-007
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 969.3 ± 4.04
PrimaryStenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12

Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.

Time frame:
12 months
Reported as:
Number · percentage of stenosis
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12
percentage of stenosisABI-007
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 1295.0
PrimaryStenosis (%) of a Non-index Lesion Using Angiography at Week 12

Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

Time frame:
12 weeks
Reported as:
Mean · percentage of stenosis
Stenosis (%) of a Non-index Lesion Using Angiography at Week 12
percentage of stenosisABI-007
Central vein50.0 ± NA
Intragraft35.0 ± 35.36
Arterial anastomosis25.0 ± NA
PrimaryStenosis (%) of a Non-index Lesion Using Angiography at Week 24

Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

Time frame:
24 weeks
Reported as:
Mean · percentage of stenosis
Stenosis (%) of a Non-index Lesion Using Angiography at Week 24
percentage of stenosisABI-007
Central vein40.0 ± NA
Intragraft45.0 ± 21.21
Arterial anastomosis27.5 ± NA
PrimaryStenosis (%) of a Non-index Lesion Using Angiography at Month 9

Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

Time frame:
9 months
Reported as:
Mean · percentage of stenosis
Stenosis (%) of a Non-index Lesion Using Angiography at Month 9
percentage of stenosisABI-007
Central vein65.0 ± NA
Intragraft57.5 ± 10.61
Arterial anastomosis25.0 ± NA
PrimaryStenosis (%) of a Non-index Lesion Using Angiography at Month 12

Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.

Time frame:
12 months
Reported as:
Number · percentage of stenosis
Stenosis (%) of a Non-index Lesion Using Angiography at Month 12
percentage of stenosisABI-007
Central veinNA ± NA
Intragraft50.0
Arterial anastomosis25.0

Adverse events

Collected over AEs collected up to 30 days after the last ABI-007 dose administration (Week 21), except for cardiovascular side effects or other events at the investigator's discretion, which would be reported whenever they occur.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABI-007—6/9 (66.7%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventABI-007
Anastomotic stenosisInjury, poisoning and procedural complications2/9
Contrast media reactionInjury, poisoning and procedural complications1/9
Graft thrombosisInjury, poisoning and procedural complications1/9
Gastrointestinal haemorrhageGastrointestinal disorders1/9
Cerebrovascular accidentNervous system disorders1/9
Most frequent other events
Showing 10 of 31
Most frequent other events
EventABI-007
Anastomotic stenosisInjury, poisoning and procedural complications3/9
Vascular graft complicationInjury, poisoning and procedural complications2/9
Neuropathy peripheralNervous system disorders2/9
DiarrhoeaGastrointestinal disorders2/9
CoughRespiratory, thoracic and mediastinal disorders2/9
Contrast media reactionInjury, poisoning and procedural complications1/9
Procedural painInjury, poisoning and procedural complications1/9
BradycardiaCardiac disorders1/9
Cardiovascular disorderCardiac disorders1/9
Hypertrophic obstructive cardiomyopathyCardiac disorders1/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)ABI-007
Mean67.6 ± 8.16
Age, Customized
Age, Customized(participants)ABI-007
<65 years4
>=65 years5
Sex: Female, Male
Sex: Female, Male(Participants)ABI-007
Female6
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ABI-007
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black of African heritage7
White, Non-Hispanic and Non-Latino2
White, Hispanic or Latino0
Other0
Weight
Weight(kg)ABI-007
Mean71.78 ± 13.271
08

Study locations

4 sites
  • Peoria, Illinois, United States
  • Shreveport, Louisiana, United States
  • Rochester, New York, United States
  • Cincinnati, Ohio, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2005 to primary completion in Nov 2007, 24 months.

Results were first posted in Mar 2012, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2005
First posted
Nov 7, 2005
StartActual
Nov 1, 2005
Primary completionActual
Nov 1, 2007
CompletionActual
Nov 1, 2007
Results first posted
Mar 13, 2012
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00249002
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 7, 2005
Start date
Nov 1, 2005
Primary completion
Nov 1, 2007
Completion
Nov 1, 2007
Results posted
Mar 13, 2012
Last update
Nov 25, 2019

Study contacts

Jose Iglesias, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion